Last week, AstraZeneca announced that its combination of Imfinzi (durvalumab) and the experimental...
- GSK’s Zejula meets primary goal in Phase III ovarian cancer trial
- Trials data suggests Cosentyx from Novartis will change psoriasis market
- Myeloma UK launches research programme to support myeloma clinical trials
- Broader inclusion criteria to double eligible cancer patients for clinical trials, finds study
- FDA accelerated review denial is a blow to Spectrum’s poziotinib
Lexicon’s reliance on risk mitigation protocols for type 1 diabetes pursuit for Zynquista elicits mixed reactions
Efforts by Lexicon Pharmaceuticals to have Zynquista approved for type 1 diabetes has split experts on whether protocols to reduce the diabetic ketoacidosis (DKA) risk will be sufficient.
IQVIA forms partnership to advance use of real-world data in trials
IQVIA has collaborated with Friends of Cancer Research to advance the use of real-world evidence (RWE) in clinical trials to better understand treatment outcomes over time.
SU2C to support clinical trials in breast and prostate cancers
Charity organisation Stand Up To Cancer (SU2C) has launched two research teams to support clinical trials involving patients with breast or prostate cancer.
Chasing Cancer considers how to improve patient access to cancer therapies
The discussion was focused on the decreasing involvement of patient participation in clinical trials and mitigation efforts taken by cancer research institutes and pharmaceutical companies.
Celgene’s Phase III study for myeloid leukaemia meets endpoints
Celgene has announced that the Phase III QUAZAR AML-001 clinical trial of CC-486 as maintenance therapy for acute myeloid leukaemia (AML) met primary and key secondary endpoints.
First-in-class HIF-2a inhibitor could revolutionise renal cell carcinoma treatment algorithm
MK-6482 is under development by Merck for the treatment of clear-cell renal cell carcinoma (RCC), metastatic RCC and glioblastoma multiforme.
Stivarga’s potential in combination therapy for metastatic colorectal cancer
To improve upon and further demonstrate the potential of Stivarga, Bayer has been actively trialling the drug in many treatment lines.
Tocagen’s cancer drug fails to improve survival in glioma trial
A Phase III clinical trial performed by Tocagen to assess its cancer immunotherapy, Toca 511 & Toca FC, has failed to meet the primary endpoint of overall survival in patients with recurrent high grade glioma (HGG), a form of brain cancer.
Exelixis and Aurigene collaborate to accelerate novel therapies for cancer
Exelixis and Aurigene Discovery Technologies have partnered to accelerate small molecules in six different projects, including three existing programmes against predetermined cancer targets.
VBI to study cancer vaccine with GSK’s adjuvant system
VBI Vaccines has partnered with GlaxoSmithKline (GSK) to assess the combination of its cancer vaccine immunotherapeutic VBI-1901 with GSK’s AS01B adjuvant system.